2018.11.03
I-Mab and Genexine Announce China IND Approval for Innovative Immunotherapy A Potential Global First-in-Class Long-Acting IL-7
SHANGHAI, Nov. 02, 2018 – I-MAB Biopharma Co., Ltd. ("I-Mab"), a Shanghai-based biotech company exclusively focused on innovative biologics in immuno-oncology and autoimmune diseases, and Genexine Inc. (KOSDAQ: 095700)...